Antibodies that reach the disease,
not the immune system.
CrossPoint Therapeutics is a biotechnology company founded in October 2022. We develop new medicines on our proprietary Stealth-Body platform, designing from the outset for what the patient can tolerate as well as for what the drug can do.
We focus on refractory diseases where clinical need is high and existing options fall short — the cases where a better-tolerated treatment would change what is possible for the patient.
Where patient well-being
and science cross.
Four principles of drug development
Application
Start from the problems where the technology is needed most.
Science
Decide on the evidence of the data.
Technology
Raise completeness through repeated validation.
Market
Shorten the time it takes to reach the patient.
CrossPoint Therapeutics strives to develop drugs that expand the range of curable disease as well as providing dignity and better life to patients.
We will diversify our Fc-silenced antibody platform into various drug modalities to target indications that are challenging and in desperate need for therapeutics.